The United Kingdom and the United States have concluded a major commercial pact that will guarantee zero tariffs on UK medicine products entering the US market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has agreed to raise spending on pharmaceuticals through the National Health Service (NHS). This pledge secures that tariffs on these crucial exports will remain at zero for a duration of 36 months.
This agreement is in response to previous statements to dramatically increase import taxes on branded drug products, with potential rates discussed reaching one hundred percent.
"This deal between the UK reinforces the global environment for new treatments and brings long-overdue balance to U.S.–U.K. drug exports," an announcement said.
Commercial Importance
Medicines are one of the the United Kingdom's most significant export categories to the US, which is clearly the biggest market for large British pharmaceutical firms.
Export figures reveal that in the year to the end of the third quarter, the UK shipped drugs totaling billions to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards jobs, increases investment and sets the stage for the UK to emerge as a worldwide center for life sciences," the Business and Trade Secretary stated.
Key British Pledges
The deal entails several key pledges from the British government:
- Price Threshold Increase: The UK will increase the affordability limit at which it deems new therapies to be prohibitively costly by a quarter.
- Higher Drug Budget: There is a target to increase overall NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Rebate Cap: The amount pharmaceutical firms must refund to the NHS to control costs will be limited at fifteen percent. Previously, refunds were more than twenty percent.
Industry Background
The pact comes amid a ongoing tension between the sector and the British authorities over medicine costs and NHS adoption.
The disagreement were intensified by arguments that American consumers were charged several times more for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large drug company projects in the UK have been halted or abandoned, while major expansions have been pledged toward projects in the United States.
The Science Minister stated that the NHS must increase expenditure on drugs, noting that its expenditure on drugs had declined as a share of its total funding over the past decade.
